Physician profile
Gary Milles
NPI 1922076405
$2,629.76
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $401 · 2021: $791 · 2022: $891 · 2023: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.35 | 2019-2023 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $350.98 | 2019-2022 | |
| Lilly USA, LLC | $243.85 | 2019-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $234.33 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $216.30 | 2020-2023 | Farxiga, Xigduo |
| Biohaven Pharmaceutical Holding Company LTD. | $182.94 | 2022 | |
| Novo Nordisk INC | $178.70 | 2020-2022 | |
| Antares Pharma, INC. | $137.26 | 2019-2022 | |
| Pfizer INC. | $98.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.74 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $91.16 | 2021-2022 | |
| Amgen INC. | $54.48 | 2021-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $54.36 | 2020-2021 | |
| Genentech USA, INC. | $43.41 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $37.22 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $36.21 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.17 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $28.16 | 2019-2022 | |
| Allergan, INC. | $26.67 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.33 | 2022 | |
| Evoke Pharma, INC. | $15.09 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.98 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2023 | Eliquis |
| Horizon Therapeutics Plc | $14.22 | 2023 | Krystexxa |
| Redhill Biopharma INC. | $13.20 | 2021 | |
| Currax Pharmaceuticals LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Milles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.